IDYA ▼ -4.6% - IDEAYA Biosciences, Inc.
$IDYA IDYA - IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
16-NOV-2026 04:06 PM ET
Share this post
More filings for $IDYA
IDYA ▲ +1.1% - IDEAYA Biosciences, Inc.Nov 15, 2026IDYA ▲ +0.1% - IDEAYA Biosciences, Inc.Nov 4, 2026IDYA ▲ +0.4% - IDEAYA Biosciences, Inc.Oct 19, 2026IDYA ▲ +2.2% - IDEAYA Biosciences, Inc.Aug 31, 2026IDYA ▲ +0.2% - IDEAYA Biosciences, Inc.Aug 28, 2026$IDYA SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $IDYA filing history →💬 Comments
Loading comments…
Leave a comment
